- Login
- Register & Subscribe
- Langue: EN FR DE
Company News
MorphoSys to more than double investment in 2009
Wednesday 28 October 2009
MorphoSys AG expects that outlays for product development and technology in 2009 will amount to between €18 million to €20 million, more than double the level a year earlier. Revenue at the German antibody company is forecast at €80 to €85 million.
Location
Germany
Genmab to receive $23 million from GSK following Arzerra approval
Tuesday 27 October 2009
Genmab A/S is set to receive DKK 116 million ($23 million) from GlaxoSmithKline following the US Food and Drug Administration’s approval of its monoclonal antibody for cancer, Arzerra (ofatumumab).
Location
Denmark
EMEA conducts review of Tysabri
Sunday 25 October 2009
The European Medicines Agency has announced a review of the multiple sclerosis drug, Tysabri (natalizumab), in light of reports of 23 cases where patients taking the drug have developed a rare brain infection known as progressive multifocal leukoencaphalopathy (PML).
Location
United Kingdom
4SC announces rights issue for existing investors
Friday 23 October 2009
The German drug discovery and development company, 4SC AG, has announced plans to raise €25 to €30 million in a rights issue to existing shareholders. The new shares are being offered at €3 per share, or at about the current market price.
Location
Germany
Novartis warns that foreign exchange losses could hurt its results
Thursday 22 October 2009
Novartis International AG has warned that foreign exchange losses could significantly reduce the growth in its reported results in 2009 even as the underlying performance of its pharmaceutical business remains strong.
Location
Switzerland
Evolva raises funds ahead of merger with Arpida
Thursday 22 October 2009
Evolva SA, a Swiss biotech company with a genetic chemistry platform, is raising CHF 28 million in the first closing of a Series B financing that will support its planned takeover of Arpida Ltd, another Swiss biotech company.
Location
Switzerland
Evotec receives €2.5 million for progress in cardiometabolic programme
Thursday 22 October 2009
Evotec AG has received a €2.5 million milestone payment from Boehringer Ingelheim (BI) for the identification of a candidate compound in a joint research programme on cardiometabolic risk. This is BI’s seventh milestone payment to Evotec.
Location
Germany
Pfizer raises revenue guidance for 2009 following Wyeth acquisition
Thursday 22 October 2009
Pfizer Inc has raised its revenue forecast for 2009 following the completion of its acquisition of Wyeth. Revenue for the year is now expected to be $49 to $50 billion compared with an earlier forecast of $45 to $46 billion, the company said.
Location
United States
Elan swings into Q3 profit following Johnson & Johnson deal
Wednesday 21 October 2009
Elan Corporation Plc said that its recent strategic alliance with Johnson & Johnson, under which it divested assets under development for Alzheimer’s disease, helped drive the company into profit for the 2009 third quarter after a loss a year earlier.
Location
Ireland
MorphoSys, Daiichi Sankyo to discover antibodies to treat nosocomial infections
Tuesday 20 October 2009
MorphoSys AG said that it has reached an agreement with Daiichi Sankyo Company Ltd of Japan to discover and develop therapeutic antibodies to treat hospital-acquired infections. The financial terms were not disclosed.
Location
Germany
Select a News Category
Recent Appointments
Pascale Witz to head strategic development at Sanofi
Monday May 6 2013
Srinivas Akkaraju joins Sofinnova Ventures
Monday May 6 2013
Vicente Anido nominated to Nicox board
Monday May 6 2013
Jeremy Farrar named director of the Wellcome Trust
Monday May 6 2013
Harry Kirsch becomes CFO at Novartis
Monday May 6 2013